FDA declines to approve Sarepta's second Duchenne drug
The U.S. Food and Drug Administration declined to approve Sarepta Therapeutics Inc's newest treatment for Duchenne muscular dystrophy (DMD), a rare muscle-wasting disorder that mainly affects boys, the company said on Monday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Boys | Food and Drug Administration (FDA) | Health | Muscular Dystrophy | Reflex Sympathetic Dystrophy